POC(Point of Care) 검사 시장 : 제품 유형, 검사 유형, 샘플 유형, 기술, 휴대성, 구입 형태, 용도, 최종사용자, 유통 채널별 - 세계 전망(2025-2030년)

The Point of Care Testing Market was valued at USD 32.87 billion in 2024 and is projected to grow to USD 37.13 billion in 2025, with a CAGR of 13.19%, reaching USD 69.17 billion by 2030.

A clear industry introduction highlighting how decentralized diagnostics, advanced assays, and digital convergence are redefining clinical decision pathways

Point of care testing continues to reshape diagnostics by bringing timely clinical decision-making closer to the patient. This introduction outlines the contemporary contours of the point of care testing ecosystem, emphasizing the convergence of decentralized diagnostics, digital connectivity, and therapeutic decision support. As health systems prioritize faster triage, value-based care, and outpatient management, point of care modalities are increasingly evaluated for their capacity to reduce clinical latency and improve patient experience.

Advances in miniaturized instrumentation, assay chemistry, and molecular methods now permit a broader range of analytes to be tested outside central laboratories. At the same time, software and connectivity tools are maturing to facilitate result integration with electronic health records and telehealth workflows. These developments are encouraging new use cases within emergency care, chronic disease monitoring, and community screening programs. Consequently, stakeholders across the value chain are recalibrating product development, reimbursement strategies, and distribution models to support rapid adoption while ensuring quality and regulatory compliance.

How converging advances in multiplexed assays, connectivity, and care delivery models are driving systemic change in decentralized diagnostic practice

The landscape of point of care testing is undergoing transformative shifts driven by technology, care delivery models, and patient expectations. First, the technological trajectory is moving from single-analyte rapid tests toward multiplexed platforms and integrated molecular workflows, enabling broader diagnostic breadth at the point of need. Concurrently, sensor miniaturization and microfluidic integration are reducing sample volume and turnaround time, which enhances feasibility for home and ambulatory environments.

Second, care delivery models are evolving: outpatient and community settings are absorbing responsibilities historically held by centralized laboratories, and telemedicine interfaces increasingly rely on near-real-time diagnostics to inform remote consultations. Third, the role of software and connectivity has intensified, with interoperability and cybersecurity becoming prerequisites for clinical adoption. Regulatory pathways are also adapting to accommodate decentralized diagnostics, creating opportunities as well as expectations for robust quality management systems. Finally, patient-centric trends-such as convenience, rapid reassurance, and longitudinal monitoring-are reshaping product design priorities, emphasizing user experience, simplified workflows, and clear result interpretation. Together, these shifts are not incremental but collectively redefine procurement decisions, clinical pathways, and competitive positioning across the ecosystem.

Assessing the multifaceted operational and supply chain consequences of United States tariff measures introduced in 2025 on point of care testing stakeholders

The imposition of tariffs and trade measures by the United States in 2025 introduces a complex set of effects for manufacturers, suppliers, and end users in the point of care testing space. Tariffs on components, consumables, and finished devices can elevate landed costs for products that rely on global supply chains, thereby influencing procurement strategies and reorder cadence. Since many instruments and reagents incorporate electronic components, plastics, and precision machined parts sourced from multiple geographies, tariff-driven cost escalation tends to be uneven and dependent on the origin of specific subcomponents.

In response to tariff pressures, manufacturers may accelerate regional sourcing strategies, increase vertical integration of critical elements, or relocate certain production activities to tariff-favored jurisdictions. These operational adjustments can mitigate exposure but often require near-term capital and redesign efforts. For healthcare providers and distributors, the cumulative effect of tariffs can shift purchasing towards products with more stable supply chain footprints, local assembly, or alternative suppliers offering comparable clinical performance. Pricing adjustments may also influence inventory policies, with stakeholders maintaining higher safety stocks to buffer against potential re-pricing or delays. Importantly, the regulatory and quality assurance implications of sourcing changes necessitate careful validation to ensure clinical equivalence, so organizations must balance cost-containment with the need to preserve test accuracy and continuity of care.

Comprehensive segmentation analysis uniting product, technology, test type, portability, purchase mode, application, end user, sample type, and distribution channel dynamics to inform strategy

Segmentation insights reveal how distinct product categories, test types, sample matrices, technologies, portability options, purchase modes, applications, end users, and distribution channels shape demand patterns and development priorities. Within product segmentation, consumables, services and software, instruments and analyzers, and reagents and assays each carry discrete implications: consumables, accessories and service maintenance and calibration, and software and connectivity underpin ongoing revenue streams and operational continuity; benchtop analyzers, molecular platforms, portable analyzers, and readers and scanners determine deployment scenarios and clinical workflows; while glucose test strips, hematology reagents, immunoassay reagents, lateral flow assay reagents, and molecular assay kits drive assay-specific supply chain and quality assurance requirements.

When viewed through test-type segmentation, the breadth from blood gases to infectious disease and molecular diagnostics affects instrument selection and clinician training, with cardiac markers and hematology requiring specialized assay robustness and coagulation testing demanding precise calibration and control across activated partial thromboplastin time, fibrinogen level, and prothrombin time and international normalized ratio assays. Infectious disease testing spans gastrointestinal, respiratory, and sexually transmitted infection panels, each influencing throughput needs and biosafety considerations. Sample-type segmentation, including blood, nasal and swab samples, saliva, and urine, informs collection device design, patient acceptability, and pre-analytical stability requirements. Technology segmentation differentiates biosensor electrochemical approaches, colorimetric platforms, immunoassays, lateral flow assays-spanning antibody, antigen, and multiplex formats-microfluidics, and PCR and molecular technologies, with each imparting trade-offs between sensitivity, specificity, cost, and operational complexity.

Portability options distinguish benchtop fixed analyzers from portable handheld devices, aligning device footprint with intended point of care settings. Mode of purchase segmentation separates over-the-counter accessibility from prescription-based dispensing, shaping labeling, user instructions, and post-market surveillance obligations. Application-driven segmentation-from chronic disease management to emergency and critical care, infectious disease diagnosis, occupational testing, oncology monitoring, and women's health-dictates performance thresholds and integration requirements with clinical care pathways. End-user segmentation that includes ambulatory care centers, diagnostic laboratories, free-standing emergency departments, home care, hospitals and clinics, and urgent care centers emphasizes differences in staffing, regulatory oversight, and capital acquisition processes. Finally, distribution channel segmentation across offline and online pathways, with offline methods such as direct sales, distributor and wholesale, and retail and pharmacy, impacts go-to-market strategies, margin structures, and customer support models. Taken together, these segmentation lenses provide a multifaceted view that guides product roadmaps, commercialization priorities, and lifecycle planning.

How geographic differences across the Americas, Europe Middle East and Africa, and Asia-Pacific shape procurement, regulation, and deployment of point of care diagnostics

Regional nuances significantly influence how point of care testing is designed, deployed, and reimbursed, with the Americas, Europe, Middle East and Africa, and Asia-Pacific each presenting distinct market drivers and operational considerations. In the Americas, health systems emphasize outpatient care optimization and chronic disease management, creating demand for devices and assays that support remote monitoring and rapid cardiovascular and metabolic testing in both clinic and home settings. Distribution networks in this region prioritize integrated supply chains and localized service support, which favors manufacturers that can demonstrate robust after-sales service and data interoperability with dominant electronic health records.

Europe, Middle East and Africa exhibit heterogeneity in regulatory regimes and healthcare infrastructure, with pockets of high regulatory rigor coexisting with areas where access barriers remain. This diversity requires adaptable product configurations and flexible pricing models. Interoperability standards and data privacy frameworks are especially influential in regulatory decision-making and clinical adoption in Europe, while capacity building and decentralized solutions are prioritized in many parts of the Middle East and Africa. In Asia-Pacific, rapid urbanization, expanding primary care networks, and high-volume public health screening initiatives drive demand for scalable, cost-effective point of care solutions. Regional manufacturing capabilities and supplier ecosystems in Asia-Pacific often accelerate product iteration cycles, and partnerships with local distributors are critical to achieve penetration across varied healthcare settings. Across all regions, reimbursement pathways, regulatory timelines, and customer training imperatives shape adoption velocity and product design choices.

Strategic competitive behaviors and platform-focused innovation that determine preparedness, resilience, and long-term differentiation within the diagnostic ecosystem

Competitive dynamics within the point of care testing landscape are characterized by strategic partnerships, platform differentiation, and a focus on integrated solutions that combine instruments, consumables, and software. Leading companies are prioritizing modular platform architectures that support multiple assay formats, enabling faster assay rollouts and improved lifetime value through recurring consumable demand. Concurrently, alliances with connectivity vendors and health IT integrators are becoming essential to deliver data-rich diagnostic results that plug into clinical workflows and population health initiatives.

Innovation strategies vary by firm, with some investing heavily in molecular and microfluidic technologies to expand the diagnostic menu, while others concentrate on low-cost lateral flow and biosensor technologies optimized for point-of-care ease of use. Service offerings, including field maintenance, calibration, and software updates, are being redefined as a competitive differentiator, and companies that can demonstrate rapid support turnaround and robust quality systems tend to secure larger institutional contracts. Supply chain resilience and localized manufacturing capabilities have also risen in strategic importance, prompting acquisitions and joint ventures to reduce exposure to global logistics disruptions. Finally, commercial models are shifting toward subscription and outcomes-based arrangements in select accounts, aligning vendor incentives with clinical performance and operational uptime.

Practical and prioritized strategic moves that companies should implement to secure adoption, supply resilience, and sustained commercial differentiation in diagnostics

To remain competitive and clinically relevant, industry leaders should pursue a set of actionable initiatives that align product development with operational realities and evolving care models. First, prioritize interoperability and user-centered software design so that devices integrate seamlessly into clinician workflows and electronic health records, thereby reducing friction at the point of adoption. Second, invest in modular platform strategies that allow rapid assay expansion and support multiple sample types, which increases flexibility for procurement teams and reduces the need for multiple device footprints.

Third, strengthen supply chain resilience through strategic regional sourcing, dual sourcing of critical components, and validated local assembly where feasible, which mitigates exposure to trade disruptions and tariff-driven cost pressures. Fourth, enhance post-market service offerings-particularly field maintenance and remote diagnostics-to preserve instrument uptime and protect clinical continuity. Fifth, adopt evidence-generation strategies that emphasize real-world performance, workflow impact, and patient-centric outcomes, thereby supporting payer discussions and clinical adoption. Finally, explore alternative commercial models, such as managed service agreements or outcome-linked contracts, to better align with healthcare purchasers' objectives and to create predictable revenue streams. Executing these actions with clear accountability and staged milestones will help firms convert technical capabilities into durable market advantage.

A transparent and reproducible research approach combining primary stakeholder interviews, rigorous secondary review, and data triangulation to validate conclusions

The research methodology underpinning this analysis integrates qualitative and quantitative approaches designed to ensure rigor, relevance, and reproducibility. Primary research consisted of in-depth interviews with clinicians, laboratory directors, procurement officers, and senior executives across device manufacturers and distributors to capture real-world use cases, procurement constraints, and unmet needs. These interviews were complemented by facility-level observations and validation of workflow integration points to translate clinical priorities into product requirements.

Secondary research included a systematic review of peer-reviewed clinical literature, regulatory guidance documents, industry standards for quality management and interoperability, and technical white papers describing assay and platform performance. Data triangulation techniques were employed to reconcile insights from diverse sources and to validate assumptions about operational behaviors and adoption barriers. The research also applied scenario analysis to assess supply chain risk and regulatory sensitivity, and key findings were stress-tested through expert panels to refine recommendations. Throughout, the methodology emphasized transparency, with audit trails linking conclusions to source materials and interview excerpts, ensuring that stakeholders can trace analytic judgments back to empirical evidence.

A conclusive synthesis emphasizing the balance between rapid diagnostic access, operational resilience, and rigorous quality controls to realize clinical impact

In conclusion, point of care testing is at an inflection point where technological maturity, changing care delivery models, and policy shifts are jointly redefining diagnostic pathways. The move toward decentralized diagnostics is supported by advances in assay chemistry, miniaturized instrumentation, and software connectivity, yet this transition also raises operational, regulatory, and supply chain challenges that require deliberate mitigation. Tariff actions, shifting procurement preferences, and regional regulatory heterogeneity add layers of complexity that stakeholders must address through resilient sourcing, adaptable product architectures, and robust evidence generation.

For manufacturers, the imperative is to deliver clinically rigorous, easy-to-use platforms that integrate seamlessly into workflows while offering sustainable service and supply models. For providers and payers, the focus should be on harnessing point of care capabilities to improve decision latency and patient experience without sacrificing quality controls. By aligning technology investments, commercial models, and implementation frameworks, stakeholders can realize the promise of point of care testing to deliver meaningful improvements in clinical care and operational efficiency.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Increasing demand for rapid, accurate diagnostics in decentralized healthcare settings and urgent care
• 5.2. Expansion of telemedicine integrating POCT for remote patient monitoring and virtual healthcare services
• 5.3. Proliferation of portable multiplex immunoassays enabling comprehensive multi-analyte panels at bedside
• 5.4. Growth of decentralized antimicrobial resistance surveillance using rapid point of care susceptibility testing assays
• 5.5. Emergence of disposable microfluidic cartridges paired with reusable analyzers to drive down per test costs
• 5.6. Increased adoption of near-patient coagulation and hemostasis monitoring for outpatient anticoagulant management and dosing
• 5.7. Integration of cloud-based quality control and centralized analytics platforms for remote device performance monitoring
• 5.8. Scaling of point of care cardiac biomarker testing in emergency departments to reduce door to treatment times
• 5.9. Investment in ruggedized diagnostics and solar powered POC devices tailored for low-resource and humanitarian deployments
• 5.10. Adoption of interoperable wireless connectivity standards to enable secure real-time transmission of POC results to EHRs

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Point of Care Testing Market, by Product

• 8.1. Introduction
• 8.2. Consumables Services & Software
  • 8.2.1. Consumables & Accessories
  • 8.2.2. Service Maintenance & Calibration
  • 8.2.3. Software & Connectivity
• 8.3. Instruments & Analyzers
  • 8.3.1. Benchtop Analyzers
  • 8.3.2. Molecular Platforms
  • 8.3.3. Portable Analyzers
  • 8.3.4. Readers & Scanners
• 8.4. Reagents & Assays
  • 8.4.1. Glucose Test Strips
  • 8.4.2. Hematology Reagents
  • 8.4.3. Immunoassay Reagents
  • 8.4.4. Lateral Flow Assay Reagents
  • 8.4.5. Molecular Assay Kits

9. Point of Care Testing Market, by Test Type

• 9.1. Introduction
• 9.2. Blood Gases
• 9.3. Cardiac Markers
  • 9.3.1. B-type Natriuretic Peptide
  • 9.3.2. Troponin
• 9.4. Comprehensive Metabolic Panel
• 9.5. Drug Of Abuse Testing
• 9.6. Hematology
  • 9.6.1. Coagulation Tests
    • 9.6.1.1. Activated Partial Thromboplastin Time
    • 9.6.1.2. Fibrinogen Level
    • 9.6.1.3. Prothrombin Time & International Normalized Ratio
  • 9.6.2. Complete Blood Count
• 9.7. Infectious Disease
  • 9.7.1. Gastrointestinal Infection Tests
  • 9.7.2. Respiratory Infection Tests
  • 9.7.3. Sexually Transmitted Infection Tests
• 9.8. Molecular Diagnostics
• 9.9. Pregnancy & Fertility
• 9.10. Urinalysis

10. Point of Care Testing Market, by Sample Type

• 10.1. Introduction
• 10.2. Blood
• 10.3. Nasal & Swab Samples
• 10.4. Saliva
• 10.5. Urine

11. Point of Care Testing Market, by Technology

• 11.1. Introduction
• 11.2. Biosensor Electrochemical
• 11.3. Colorimetric Platforms
• 11.4. Immunoassay
• 11.5. Lateral Flow Assays
  • 11.5.1. Antibody Tests
  • 11.5.2. Antigen Tests
  • 11.5.3. Multiplex Lateral Flow
• 11.6. Microfluidics
• 11.7. PCR And Molecular

12. Point of Care Testing Market, by Portability

• 12.1. Introduction
• 12.2. Benchtop Fixed Analyzers
• 12.3. Portable Handheld Devices

13. Point of Care Testing Market, by Mode of Purchase

• 13.1. Introduction
• 13.2. Over-The-Counter Tests
• 13.3. Prescription-Based Tests

14. Point of Care Testing Market, by Application

• 14.1. Introduction
• 14.2. Chronic Disease Management
• 14.3. Emergency And Critical Care
• 14.4. Infectious Disease Diagnosis
• 14.5. Occupational And Workplace Testing
• 14.6. Oncology Monitoring
• 14.7. Women Health

15. Point of Care Testing Market, by End User

• 15.1. Introduction
• 15.2. Ambulatory Care Centers
• 15.3. Diagnostic Laboratories
• 15.4. Free-Standing Emergency Departments
• 15.5. Home Care
• 15.6. Hospitals & Clinics
• 15.7. Urgent Care Centers

16. Point of Care Testing Market, by Distribution Channel

• 16.1. Introduction
• 16.2. Offline
  • 16.2.1. Direct Sales
  • 16.2.2. Distributor & Wholesale
  • 16.2.3. Retail & Pharmacy
• 16.3. Online

17. Americas Point of Care Testing Market

• 17.1. Introduction
• 17.2. United States
• 17.3. Canada
• 17.4. Mexico
• 17.5. Brazil
• 17.6. Argentina

18. Europe, Middle East & Africa Point of Care Testing Market

• 18.1. Introduction
• 18.2. United Kingdom
• 18.3. Germany
• 18.4. France
• 18.5. Russia
• 18.6. Italy
• 18.7. Spain
• 18.8. United Arab Emirates
• 18.9. Saudi Arabia
• 18.10. South Africa
• 18.11. Denmark
• 18.12. Netherlands
• 18.13. Qatar
• 18.14. Finland
• 18.15. Sweden
• 18.16. Nigeria
• 18.17. Egypt
• 18.18. Turkey
• 18.19. Israel
• 18.20. Norway
• 18.21. Poland
• 18.22. Switzerland

19. Asia-Pacific Point of Care Testing Market

• 19.1. Introduction
• 19.2. China
• 19.3. India
• 19.4. Japan
• 19.5. Australia
• 19.6. South Korea
• 19.7. Indonesia
• 19.8. Thailand
• 19.9. Philippines
• 19.10. Malaysia
• 19.11. Singapore
• 19.12. Vietnam
• 19.13. Taiwan

20. Competitive Landscape

• 20.1. Market Share Analysis, 2024
• 20.2. FPNV Positioning Matrix, 2024
• 20.3. Competitive Analysis
  • 20.3.1. F. Hoffmann-La Roche Ltd
  • 20.3.2. Abbott Laboratories
  • 20.3.3. Abaxis, Inc. by Zoetis Inc
  • 20.3.4. AccuBioTech Co., Ltd.
  • 20.3.5. ACON Laboratories, Inc.
  • 20.3.6. Beckman Coulter
  • 20.3.7. Becton, Dickinson and Company
  • 20.3.8. Bio-Rad Laboratories, Inc.
  • 20.3.9. bioMerieux SA
  • 20.3.10. CardioGenics Holdings Inc.
  • 20.3.11. Chembio Diagnostic Systems, Inc. by Biosynex
  • 20.3.12. Danaher Corporation
  • 20.3.13. EKF Diagnostics Holdings
  • 20.3.14. GE Healthcare Technologies, Inc.
  • 20.3.15. Medtronic Plc
  • 20.3.16. Nova Biomedical Corporation
  • 20.3.17. OraSure Technologies, Inc.
  • 20.3.18. Quidel Corporation
  • 20.3.19. Radiometer Medical ApS
  • 20.3.20. Randox Laboratories Ltd.
  • 20.3.21. Siemens Healthineers AG
  • 20.3.22. Thermo Fisher Scientific Inc.

21. ResearchAI

22. ResearchStatistics

23. ResearchContacts

24. ResearchArticles

25. Appendix